Physician profile
Steven D Gronowitz
NPI 1093772030
$13,343.10
in general payments reported to CMS, 2019-2025
57 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $1,201 · 2021: $1,499 · 2022: $1,603 · 2023: $1,948 · 2024: $3,072 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,650 · Debt Forgiveness: $731 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,649.89 |
| Debt Forgiveness | $730.62 |
| Education | $198.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,490.58 | 2019-2025 | |
| Janssen Biotech, INC. | $1,442.44 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,390.17 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $931.59 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Olympus America INC. | $730.62 | 2024 | Gastrointestinal Videoscope |
| Ironwood Pharmaceuticals, INC | $673.36 | 2020-2024 | Linzess |
| Qol Medical, LLC | $663.81 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $425.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $402.40 | 2019-2025 | Ocaliva |
| Pfizer INC. | $363.60 | 2019-2025 | |
| Gilead Sciences, INC. | $347.09 | 2019-2025 | |
| Lilly USA, LLC | $267.72 | 2019-2025 | Omvoh |
| Celgene Corporation | $224.44 | 2021-2023 | Zeposia |
| Vivus LLC | $223.69 | 2020-2025 | Qsymia, Pancreaze |
| Redhill Biopharma INC. | $222.38 | 2020-2023 | Talicia, Aemcolo, Movantik |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gronowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.